Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
The purpose of this study is to evaluate the safety and efficacy of multiple intravenous
 doses of pegol-Sihematide in participants with chronic kidney disease (CKD) who are on
 dialysis.
Inclusion Criteria:

 1. Males or females≥18 and≤70, Weight ≥ 45 kilograms (kg)

 2. Participants with chronic renal failure on dialysis for ≥ 3 months prior to
 randomization.

 3. On ESAs treatment for ≥8 weeks prior to randomization with stable doses and the
 average doses ≤ 10000 IU/week

 4. Hemoglobin values of ≥ 10.0 and≤ 12.0 g/dL at Screening

 5. Patients with a transferrin saturation≥ 20% and a ferritin≥ 100 ng/mL. vitamin B12 and
 folic acid level above lower limit of normal.

 6. Signed informed consent

 Exclusion Criteria:

 1. Pregnant or lactating females

 2. Red blood cell transfusion within 3 months prior to randomization

 3. Known intolerance to any erythropoiesis stimulating agent (ESA) or pegylated molecule
 or to all parenteral iron supplementation products

 4. hemolytic syndromes or coagulation disorder

 5. hematological disease (including but not limited to myelodysplastic syndrome,
 hematological malignancy, , hemoglobinopathy, pure red cell aplasia),

 6. Chronic, uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid
 arthritis, systemic lupus erythematosus, etc.);

 7. C Reactive Protein (CRP) greater than 30 mg/L within the 4 weeks prior to
 randomization

 8. Uncontrolled or symptomatic secondary hyperparathyroidism(iPTH>800pg/ml)

 9. Poorly controlled hypertension within 4 weeks prior to randomization

 10. Chronic congestive heart failure (New York Heart Association Class Ⅲ or IV)

 11. significant symptom within 6 months prior to randomization (e.g. myocardial
 infarction, serious or precarious coronary artery disease,stroke, respiratory disease,
 autoimmune disease, neuropathy, phrenopathy, hepatopathy including Active hepatitis B,
 Active hepatitis C, A positive test for HIV antibody or ALT> 2 x upper limit of normal
 (ULN), AST> 2 x upper limit of normal (ULN))

 12. tumor malignancy

 13. Expected survival less than 12 months

 14. A scheduled kidney transplant

 15. Major surgery (may Massive bleeding) during the study

 16. expected conception within 4 Weeks after the end of the Study Treatment

 17. The subject has participated in other clinical trial within the 12 weeks prior to
 randomization

 18. Have any other condition or prior therapy that, in the investigator's opinion, would
 make the subject unsuitable for the study, or unable or unwilling to comply with the
 study procedures